Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission : a retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd..
Thiotepa is an alkylating compound with an antineoplastic and myeloablative activity and can mimic the effect of radiation. However, it is unknown whether this new regimen could safely replace the long-established ones. This retrospective matched-pair analysis evaluated the outcome of adults with acute myeloid leukaemia in first complete remission who received myeloablative conditioning either with a thiotepa-based (n = 121) or a cyclophosphamide/total body irradiation-based (TBI; n = 358) regimen for allogeneic hematopoietic stem cell transplantation from an HLA-matched sibling or an unrelated donor. With a median follow-up of 44 months, the outcome was similar in both groups. Acute graft-versus-host disease grade II-IV was observed in 25% after thiotepa-containing regimen versus 35% after TBI (P = 0.06). The 2-yr cumulative incidence of chronic graft-versus-host disease was 40.5% for thiotepa and 41% for TBI (P = 0.98). At 2 yrs, the cumulative incidences of non-relapse mortality and relapse incidence were 23.9% (thiotepa) vs. 22.4% (TBI; P = 0.66) and 17.2% (thiotepa) vs. 23.3% (TBI; P = 0.77), respectively. The probabilities of leukaemia-free and overall survival at 2 yrs were not significantly different between the thiotepa and TBI groups, at 58.9% vs. 54.2% (P = 0.95) and 61.4% vs. 58% (P = 0.72), respectively. Myeloablative regimens using combinations including thiotepa can provide satisfactory outcomes, but the optimal conditioning remains unclear for the individual patient in this setting.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2016 |
|---|---|
| Erschienen: |
2016 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:96 |
|---|---|
| Enthalten in: |
European journal of haematology - 96(2016), 1 vom: 25. Jan., Seite 90-7 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Eder, Sandra [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
8N3DW7272P |
|---|
| Anmerkungen: |
Date Completed 10.10.2016 Date Revised 30.12.2016 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ejh.12553 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM247415065 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM247415065 | ||
| 003 | DE-627 | ||
| 005 | 20231224145145.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ejh.12553 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0824.xml |
| 035 | |a (DE-627)NLM247415065 | ||
| 035 | |a (NLM)25807864 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Eder, Sandra |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Thiotepa-based versus total body irradiation-based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission |b a retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation |
| 264 | 1 | |c 2016 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 10.10.2016 | ||
| 500 | |a Date Revised 30.12.2016 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. | ||
| 520 | |a Thiotepa is an alkylating compound with an antineoplastic and myeloablative activity and can mimic the effect of radiation. However, it is unknown whether this new regimen could safely replace the long-established ones. This retrospective matched-pair analysis evaluated the outcome of adults with acute myeloid leukaemia in first complete remission who received myeloablative conditioning either with a thiotepa-based (n = 121) or a cyclophosphamide/total body irradiation-based (TBI; n = 358) regimen for allogeneic hematopoietic stem cell transplantation from an HLA-matched sibling or an unrelated donor. With a median follow-up of 44 months, the outcome was similar in both groups. Acute graft-versus-host disease grade II-IV was observed in 25% after thiotepa-containing regimen versus 35% after TBI (P = 0.06). The 2-yr cumulative incidence of chronic graft-versus-host disease was 40.5% for thiotepa and 41% for TBI (P = 0.98). At 2 yrs, the cumulative incidences of non-relapse mortality and relapse incidence were 23.9% (thiotepa) vs. 22.4% (TBI; P = 0.66) and 17.2% (thiotepa) vs. 23.3% (TBI; P = 0.77), respectively. The probabilities of leukaemia-free and overall survival at 2 yrs were not significantly different between the thiotepa and TBI groups, at 58.9% vs. 54.2% (P = 0.95) and 61.4% vs. 58% (P = 0.72), respectively. Myeloablative regimens using combinations including thiotepa can provide satisfactory outcomes, but the optimal conditioning remains unclear for the individual patient in this setting | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a acute myeloid leukaemia | |
| 650 | 4 | |a allo-HSCT | |
| 650 | 4 | |a thiotepa | |
| 650 | 4 | |a total body irradiation | |
| 650 | 7 | |a Cyclophosphamide |2 NLM | |
| 650 | 7 | |a 8N3DW7272P |2 NLM | |
| 650 | 7 | |a Thiotepa |2 NLM | |
| 650 | 7 | |a 905Z5W3GKH |2 NLM | |
| 700 | 1 | |a Labopin, Myriam |e verfasserin |4 aut | |
| 700 | 1 | |a Arcese, William |e verfasserin |4 aut | |
| 700 | 1 | |a Or, Reuven |e verfasserin |4 aut | |
| 700 | 1 | |a Majolino, Ignazio |e verfasserin |4 aut | |
| 700 | 1 | |a Bacigalupo, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a de Rosa, Gennaro |e verfasserin |4 aut | |
| 700 | 1 | |a Volin, Liisa |e verfasserin |4 aut | |
| 700 | 1 | |a Beelen, Dietrich |e verfasserin |4 aut | |
| 700 | 1 | |a Veelken, Hendrik |e verfasserin |4 aut | |
| 700 | 1 | |a Schaap, Nicolaas P M |e verfasserin |4 aut | |
| 700 | 1 | |a Kuball, Jurgen |e verfasserin |4 aut | |
| 700 | 1 | |a Cornelissen, Jan |e verfasserin |4 aut | |
| 700 | 1 | |a Nagler, Arnon |e verfasserin |4 aut | |
| 700 | 1 | |a Mohty, Mohamad |e verfasserin |4 aut | |
| 700 | 0 | |a Acute Leukemia Working Party |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of haematology |d 1990 |g 96(2016), 1 vom: 25. Jan., Seite 90-7 |w (DE-627)NLM01261727X |x 1600-0609 |7 nnns |
| 773 | 1 | 8 | |g volume:96 |g year:2016 |g number:1 |g day:25 |g month:01 |g pages:90-7 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ejh.12553 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 96 |j 2016 |e 1 |b 25 |c 01 |h 90-7 | ||